Process Optimization For Monoclonal Antibody (mAb) Commercial Manufacturing

By Daniel Pirsch, MS, Senior Scientist,, Upstream Process Development, Catalent Biologics; Nicole Kavanaugh, Ph.D., Manager, Downstream Process Development, Catalent Biologics; and Michael Buckley, Ph.D., Principal, SimpleCMC Consulting

The transition from early- to late-stage clinical trials marks a critical milestone, signaling promising clinical results and the need to prepare for regulatory submission and potential commercialization. At this stage, sponsors must assess whether their manufacturing capabilities — such as facilities, equipment, workforce, and expertise—are sufficient to support larger-scale production.

It is also essential to review existing data and analytical methods to determine whether the current process can be effectively scaled. Because early-stage trials typically generate limited data, additional analysis and expanded product characterization may be required to meet regulatory expectations.

As programs advance, sponsors may find their current manufacturing setup inadequate for late-stage development and commercial supply. This often leads to transferring the process to a contract development and manufacturing organization (CDMO) with the capacity, technology, and experience to support scale-up and launch. Selecting the right CDMO — and building a strong, collaborative partnership — is key to ensuring successful process optimization, commercialization, and long-term product lifecycle management